Evolocumab produced a 31% relative risk reduction in major cardiovascular events.
Nicholas Marston, MD, MPH
Advertisement
Articles by Nicholas Marston, MD, MPH
Olezarsen effectively lowers triglycerides and enhances cardiovascular health, especially when combined with fibrates, benefiting pharmacists and patients alike.
New triglyceride-lowering therapy Olezarsen significantly reduces severe hypertriglyceridemia and acute pancreatitis risk, offering hope for patients.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
2
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
3
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
4
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
5